Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
- PMID: 38717927
- DOI: 10.1080/17474086.2024.2353751
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma
Keywords: BCMA; Myeloma; bispecific antibodies; elranatamab; teclistamab.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials